Intest Res.
2017 Apr;15(2):147-148. 10.5217/ir.2017.15.2.147.
Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
- Affiliations
-
- 1Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. jpim0911@snu.ac.kr
- KMID: 2425154
- DOI: http://doi.org/10.5217/ir.2017.15.2.147
Abstract
- No abstract available.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
- Factors Affecting Surgical Treatment With Infliximab Therapy in Perianal Fistula With Crohn Disease
- Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study
- Surgical treatment of perianal fistula in Crohn's disease
- Comparative effectiveness of ustekinumab versus infliximab in the management of perianal fistulizing Crohn's disease: a retrospective study in China
